Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;20(6):e201023222418.
doi: 10.2174/0115733998253672231011161400.

A Review on Diabetic Retinopathy

Affiliations
Review

A Review on Diabetic Retinopathy

Vijender Kour et al. Curr Diabetes Rev. 2024.

Abstract

Diabetic retinopathy is a well-recognised microvascular complication of diabetes and is among the leading cause of blindness all over the world. Over the last decade, there have been advances in the diagnosis of diabetic retinopathy and diabetic macular edema. At the same time, newer therapies for the management of diabetic retinopathy have evolved. As a result of these advances, a decline in severe vision loss due to diabetes has been witnessed in some developing countries. However, there is a steady increase in the number of people affected with diabetes, and is expected to rise further in the coming years. Therefore, it is prudent to identify diabetic retinopathy, and timely intervention is needed to decrease the burden of severe vision loss. An effort has been made to review all the existing knowledge regarding diabetic retinopathy in this article and summarize the present treatment options for diabetic retinopathy.

Keywords: Diabetic retinopathy (DR); anti-VEGF therapy; diabetic macular edema (DME); laser photocoagulation.; nonproliferative diabetic retinopathy (NPDR); proliferative diabetic retinopathy (PDR).

PubMed Disclaimer

LinkOut - more resources